Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 Growth Stocks Insiders Are Betting On

In This Article:

In recent days, the U.S. stock market has experienced a mix of volatility and cautious optimism, with major indices like the Dow Jones and S&P 500 losing ground after a brief winning streak amid ongoing concerns about economic data and corporate earnings. As investors navigate these turbulent times, growth companies with high insider ownership often attract attention due to their potential for long-term value creation and the confidence insiders demonstrate through significant stakes in their own firms.

Top 10 Growth Companies With High Insider Ownership In The United States

Name

Insider Ownership

Earnings Growth

Super Micro Computer (NasdaqGS:SMCI)

25.6%

29.8%

Hims & Hers Health (NYSE:HIMS)

13.2%

21.8%

Duolingo (NasdaqGS:DUOL)

14.4%

37.5%

Credo Technology Group Holding (NasdaqGS:CRDO)

12.2%

65.1%

Niu Technologies (NasdaqGM:NIU)

36%

82.8%

Astera Labs (NasdaqGS:ALAB)

15.8%

61.4%

Clene (NasdaqCM:CLNN)

19.4%

64%

Upstart Holdings (NasdaqGS:UPST)

12.6%

100.2%

BBB Foods (NYSE:TBBB)

16.2%

29.6%

Credit Acceptance (NasdaqGS:CACC)

14.4%

33.8%

Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Harrow

Simply Wall St Growth Rating: ★★★★★☆

Overview: Harrow, Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products with a market cap of approximately $910.96 million.

Operations: Harrow's revenue is primarily derived from its Branded segment, which generated $116.12 million, and the ImprimisRx segment, contributing $83.50 million.

Insider Ownership: 15.6%

Earnings Growth Forecast: 73.9% p.a.

Harrow is positioned for significant growth, with revenue expected to increase by 31.8% annually, outpacing the broader U.S. market. Recent strategic moves include a partnership with Nordic Pharma to launch a generic Maxitrol® and an expansion of its VEVYE® Access for All program, enhancing patient access and affordability. Despite past losses, Harrow's financial outlook is improving with projected profitability within three years and substantial revenue guidance of over US$280 million for 2025.

NasdaqGM:HROW Ownership Breakdown as at Apr 2025
NasdaqGM:HROW Ownership Breakdown as at Apr 2025

Allegiant Travel

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Allegiant Travel Company is a leisure travel provider offering services and products to residents of under-served U.S. cities, with a market cap of approximately $817.75 million.